Cardiff, UK, March 17, 2023 – TrakCelAnd The leading provider of cellular coordination solutions for clinical trials and commercial therapies to the Cell and Gene Therapy (CGT) industry, today announced the latest milestone in the collaboration between TrakCel and Lonza, a global development and manufacturing partner for the pharmaceutical, biotechnology and nutritional industries.
This collaboration resulted in a safe and reliable combination of TrakCel’s OCELLOS cell orchestration platform and Lonza’s MODA-ES(R) manufacturing platform. The integration between OCELLOS and MODA-ES(R) will mean that critical manufacturing steps, inspections and data flow directly into the chain of custody and chain of identity within the CGT supply chain, without a missed or missed patient journey. This will help developers gain additional visibility and control while reducing product loss, processing delays, recalls, and poor quality products. TrakCel and Lonza have just completed a proof of work integration of concept. As a result, embedded solutions are immediately available on the market.
The integration is the latest part of the ongoing collaboration between TrakCel and Lonza. This collaboration includes a multi-phase launch of connectivity with OCELLOS for other Lonza systems including SAP and LIMs. As a result, TrakCel has solidified OCELLOS in a central position for an integrated coordination ecosystem. Other integrations are scheduled to follow the MES proof of concept and are likely to be completed in the second half of 2023.
These future mergers will allow OCELLOS users to pull more information or documents required to drive operations or support chain of custody and identity chain directly to OCELLOS in real time. Integrations like this allow TrakCel’s CGT supply and value chain clients to configure a network of systems to best meet their operations.
“The flow of cell and gene therapies toward commercialization continues to increase in number and speed. It is essential that supply and value chains continue to keep pace with patient service demands following therapeutic approvals and commercialization processes. Effective use of resources will be essential to streamlining the costs of bringing these therapies to market,” said Dr. Fiona Withey, CEO of TrakCel. As a result, TrakCel has partnered with a range of organizations that will increase visibility across supply and value chains and reduce risk as patient numbers continue to grow. TrakCel / Lonza cooperation will allow Track customers more accurately in the supply chain process than ever before and fulfill a range of tasks to monitor and schedule manufacturing and equipment lead times to reduce waste and delays. In 2021, nearly four-fifths of biological recoveries were the result of a failed process step or lack of documentation. TrakCel is working hard to ensure that this significant waste is stopped.”
For today’s cell and gene therapy industry, coordination within the manufacturing component of the supply chain will be essential. Both manual and automated manufacturing of autologous and allogeneic therapies will require accurate tracking of large numbers of patients in the very near future.” said Walter Pane, director, head of cell, genetics and labeling, at Lonza. “Integration of our manufacturing platform with TrakCel’s OCELLOS will be the first step in a multi-phase rollout of integrations between Lonza and TrakCel that will Further improve adherence to process and critical records, enhance treatment safety and reduce costly errors. “